Evidence map›Paper›PMID 38567516›Full record

ArticleEuropean journal of neurology2024

Real-world persistence of multiple sclerosis disease-modifying therapies.

Emma C Tallantyre, Ruth Dobson, Joseph L J Froud, Frederika A St John, Valerie M Anderson, Tarunya Arun, Lauren Buckley, Nikos Evangelou, Helen L Ford, Ian Galea and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 15 institutions in 1 country.

Emma C TallantyreDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.ORCID 0000-0002-3760-6634
Ruth DobsonPreventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, London, UK.ORCID 0000-0002-2993-585X
Joseph L J FroudDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Frederika A St JohnDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Valerie M AndersonDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Tarunya ArunDepartment of Neuroscience, University Hospitals Coventry and Warwickshire, Coventry, UK.
Lauren BuckleyDepartment of Neurology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Nikos EvangelouNottingham Centre for Multiple Sclerosis and Neuroinflammation, Queen's Medical Centre, University Hospitals NHS Trust, Nottingham, UK.
Helen L FordCentre for Neurosciences, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, UK.
Ian GaleaClinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.ORCID 0000-0002-1268-5102
Sumi GeorgeDepartment of Neurology, Ulster Hospital, Dundonald, UK.
Orla M GrayDepartment of Neurology, Ulster Hospital, Dundonald, UK.
Aimee M HibbertNottingham Centre for Multiple Sclerosis and Neuroinflammation, Queen's Medical Centre, University Hospitals NHS Trust, Nottingham, UK.
Mo HuDepartment of Neurology, Swansea University Health Board, Swansea, UK.
Stella E HughesMS Clinic, Belfast City Hospital, Belfast, UK.
Gillian IngramDepartment of Neurology, Swansea University Health Board, Swansea, UK.
Seema KalraNeurology Department, University Hospital North Midlands NHS Trust, Stoke-on-Trent, UK.
Chia-Hui E LimDepartment of Neurology, Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Joela T M MathewsBarts Health NHS Trust, London, UK.
Gavin V McDonnellMS Clinic, Belfast City Hospital, Belfast, UK.
Naomi MescallQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK.
Sam NorrisAneurin Bevan University Health Board, Department of Neurology, Royal Gwent Hospital, Newport, UK.
Stephen J RamsayMS Clinic, Belfast City Hospital, Belfast, UK.
Claire M RiceDepartment of Neurology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
Melanie J RussellCentre for Neurosciences, Leeds Teaching Hospitals NHS Trust, Leeds General Infirmary, Leeds, UK.
Marianne J Shawe-TaylorQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK.
Thomas E WilliamsQueen Square Multiple Sclerosis Centre, Department of Neuroinflammation, University College London, London, UK.ORCID 0000-0002-8197-0177
Katharine E HardingAneurin Bevan University Health Board, Department of Neurology, Royal Gwent Hospital, Newport, UK.
Neil P RobertsonDivision of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Queen Mary University of London · GBUniversity of Ulster · GBCardiff University · GBLeeds General Infirmary · GBNorth Bristol NHS Trust · GBNottingham University Hospitals NHS Trust · GBRoyal Gwent Hospital · GBSwansea Bay University Health Board · GBUlster Hospital · GBUniversity Hospital of Wales · GBUniversity Hospital Southampton NHS Foundation Trust · GBBarts Health NHS Trust · GBSt Thomas' Hospital · GBUniversity Hospital Coventry · GBUniversity Hospitals of North Midlands NHS Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeTreatment persistence is the continuation of therapy over time. It reflects a combination of treatment efficacy and tolerability. We aimed to describe real-world rates of persistence on disease-modifying therapies (DMTs) for people with multiple sclerosis (pwMS) and reasons for DMT discontinuation.

methodsTreatment data on 4366 consecutive people with relapse-onset multiple sclerosis (MS) were pooled from 13 UK specialist centres during 2021. Inclusion criteria were exposure to at least one MS DMT and a complete history of DMT prescribing. PwMS in blinded clinical trials were excluded. Data collected included sex, age at MS onset, age at DMT initiation, DMT treatment dates, and reasons for stopping or switching DMT. For pwMS who had received immune reconstituting therapies (cladribine/alemtuzumab), discontinuation date was defined as starting an alternative DMT. Kaplan-Meier survival analyses were used to express DMT persistence.

resultsIn 6997 treatment events (1.6 per person with MS), median time spent on any single maintenance DMT was 4.3 years (95% confidence interval = 4.1-4.5 years). The commonest overall reasons for DMT discontinuation were adverse events (35.0%) and lack of efficacy (30.3%). After 10 years, 20% of people treated with alemtuzumab had received another subsequent DMT, compared to 82% of people treated with interferon or glatiramer acetate.

conclusionsImmune reconstituting DMTs may have the highest potential to offer a single treatment for relapsing MS. Comparative data on DMT persistence and reasons for discontinuation are valuable to inform treatment decisions and in personalizing treatment in MS.

Indexed as

Multiple Sclerosis, Relapsing-RemittingAdultDrug MonitoringFemaleHumansImmunologic FactorsMaleMiddle AgedMultiple SclerosisImmunologic Factorsdisease‐modifying therapymultiple sclerosispersistencetreatment

Identifiers

PMID38567516
PMCPMC11235620
OpenAlexW4393902158

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.